Lumigan, Allergan’s Intraocular Pressure Drug, Received FDA Approval

The FDA has approved Allergan's once-daily prescription eye drop Lumigan as a first-line treatment for elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.

The Lumigan first-line indication is in addition to the product's already established use as a second-line treatment, for which the FDA approved the drug in 2001.

Since its introduction as a first-line treatment, Lumigan has been widely prescribed by eye care professionals to reduce elevated intraocular pressure (IOP) in patients who were intolerant of other IOP-lowering medications or who did not have a sufficient reduction in IOP in multiple measurements using other medications for the disorder.

Elevated IOP represents a major risk factor for vision loss associated with open-angle glaucoma; the higher the IOP, the greater the likelihood of optic nerve damage, which can lead to vision loss and potential blindness.

Source: Pharmaceutical-Business-Review


No Responses to “Lumigan, Allergan’s Intraocular Pressure Drug, Received FDA Approval”

  1. Jeanette White Says:

    Would appreciate contact for help getting lumigan, as I have reached the limit my part D prescription insurance. I can not afford it . I have had reactions to other eye meds.

Leave a Reply

Protected by Comment Guard Pro